GLP-1s and NAION: What Clinicians Should Know
Summary
Neuro-ophthalmologist Andrew Lee, MD, discusses the FDA’s new labeling change about a rare cause of vision loss and how to weigh the benefits and risks of GLP-1 treatment.
Description from Medscape.
Who is covering this
-
GLP-1s and NAION: What Clinicians Should Know
Neuro-ophthalmologist Andrew Lee, MD, discusses the FDA’s new labeling change about a rare cause of vision loss and how to weigh the benefits and risks of GLP-1 treatment.






Comments
Comments need JavaScript.